About the mpox vaccine

Since 2013, Imvanex® has been registered in Europe as a vaccine that protects against smallpox. As of 22 July 2022, Imvanex® is also registered as a vaccine against mpox. Imvanex® contains a live attenuated virus that cannot replicate inside the body. It has milder side effects than the old smallpox vaccinations, and Imvanex® does not leave a scar.

The vaccination against mpox consists of 2 injections with an interval of at least 4 weeks.

It is not known whether vaccination with Imvanex® can prevent all symptoms of mpox or transmission of the virus. It is possible that some people may still develop a mild form of the disease. They may transmit the virus despite vaccination.

Even after vaccination, the following recommendations apply:

• Have any blisters examined by your GP or the Municipal Public Health Services (GGDs).
• Do not have any intimate contact or sexual intercourse – not even with a condom – until the scabs have fallen off and new, healed skin has formed.

If a person tests positive for mpox, they need to self-isolate (stay at home) and follow the  rules for isolation.

The vaccine is safe for people whose immune system does not work properly due to illness or medication. However, immunocompromised people may be less well protected against mpox.